Advertisement
*
Reproduction permitted for personal use only. For reprints and reprint permission, contact reprints@wistechnology.com.

GE begins human trials for cancer detection agent

Madison, Wis. - Medical imaging technology provider GE Healthcare announced it has begun clinical trials of a new molecular imaging agent for the detection of cancer.

The agent, which uses positron emission tomography (PET), is designed to track the process of angiogenesis, or the formation of new blood vessels in the body. It will be used to quantify therapy for Stage IV metastatic tumors in breast cancer patients, before and after chemotherapy.

In a PET treatment, patients are injected with small amounts of radiopharmaceuticals, which create images of tissue chemical changes that could be early warning signs of cancer. Uses for the radiopharmaceuticals include spotting changes in glucose metabolism, monitoring the effectiveness of drug therapy during cancer treatments, and tracking whether tumors are diverting new blood vessels to sustain their growth.

The research is being overseen at the Hammersmith Hospital in London by David Brooks, chief medical officer of GE Imanet, which handles GE Healthcare's international network of imaging research centers.

GE Healthcare is a division of General Electric. The company manufactures medical imaging technology at its Waukesha headquarters, GE Healthcare Technologies, and its Milwaukee location, GE Healthcare Information Technologies.
Advertisement
Related stories

Michael Rosen: Midwest retains dominant role in 2005 world medical device market

GE announces first installation of Discovery VCT

GE, St. Jude to collaborate on visualization technology

-Add Your Comment

Name:
E-mail:

Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and are not immediately posted. Your email address will not be posted.

WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact edit@wistechnology.com.

WTN Media Presents